Back to top

Image: Bigstock

Why Lazard (LAZ) is Poised to Beat Earnings Estimates (Again)

Read MoreHide Full Article

Looking for a stock that might be in a good position to beat earnings at its next report? Consider Lazard Ltd (LAZ - Free Report) , a firm in the Financial - Investment Management industry, which could be a great candidate for another beat.

This company has seen a nice streak of beating earnings estimates, especially when looking at the previous two reports. In fact, in these reports, LAZ has beaten estimates by at least 15% in both cases, suggesting it has a nice short-term history of crushing expectations.

Earnings in Focus

Two quarters ago, LAZ expected to post 80 cents per share, while it actually produced 98 cents per share, a beat of 22.5%.  Meanwhile, for the most recent quarter, the company looked to deliver 73 cents per share, when it actually saw earnings 85 cents per share instead, representing a 16.4% positive surprise.

Lazard Ltd. Price and EPS Surprise

Lazard Ltd. Price and EPS Surprise | Lazard Ltd. Quote

 

Thanks in part to this history, recent estimates have been moving higher for Lazard.In fact, the Earnings ESP for LAZ is positive, which is a great sign of a coming beat.

After all, the Zacks Earnings ESP compares the most accurate estimate to the broad consensus, looking to find stocks that have seen big revisions as of late, suggesting that analysts have recently become more bullish on the company’s earnings prospects. This is the case for LAZ, as the firm currently has a Zacks Earnings ESP of +2.69%, so another beat could be around the corner.

This is particularly true when you consider that LAZ has a great Zacks Rank #2 (Buy) which can be a harbinger of outperformance and a signal for a strong earnings profile. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

When you add this solid Zacks Rank to a positive Earnings ESP, a positive earnings surprise happens nearly 70% of the time, so it seems pretty likely that LAZ could see another beat at its next report, especially if recent trends are any guide.

Investor Alert: Breakthroughs Pending

A medical advance is now at the flashpoint between theory and realization. Billions of dollars in research have poured into it. Companies are already generating substantial revenue, and even more wondrous products are in the pipeline.

Cures for a variety of deadly diseases are in sight, and so are big potential profits for early investors. Zacks names 5 stocks to buy now.

Click here to see them >>


See More Zacks Research for These Tickers


Normally $25 each - click below to receive one report FREE:


Lazard, Inc. (LAZ) - free report >>

Published in